Progress, Potential, and Possibilities Podcast / Show

Send us a textDr. Ha Hong, Ph.D. ( http://hahong.org/ ), is Chief Artificial Intelligence Officer at Medtronic Endoscopy ( https://www.medtronic.com/covidien/en-us/clinical-solutions/gastrointestinal-health.html ) where he oversees AI R&D and strategy, emphasizing building responsible AI solutions for patient care, and has a track record of inventing and delivering breakthrough technologies in the medical device field ( https://www.medtronic.com/covidien/en-us/products/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy.html ). Before joining Medtronic, Dr. Hong was a founding team member and the Chief Architect at Caption Health, which GE HealthCare acquired, where he led the R&D, including the development of the first commercially available AI navigation system for cardiac ultrasound examination. Dr. Hong has a Ph.D. in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology Program and a BS in Physics from the Korea Advanced Institute of Science and Technology. Medtronic Edonscopy is part of Medtronic plc (https://www.medtronic.com/us-en/index.html), the world’s largest medical device company, which operates in more than 150 countries and employs over 90,000 people. Important Episode Links Medtronic GI Genius™ Intelligent Endoscopy Module - https://www.medtronic.com/covidien/en-us/products/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy.html Medtronic Artificial Intelligence (AI) Compass for responsible use of AI - https://www.medtronic.com/content/dam/medtronic-wide/public/brand-corporate-assets/resources/medtronic-ai-compass.pdf Dr. Ha Hong Linkedin Profile - https://www.linkedin.com/in/ha-hong/ Support the show

Send us a textDr. Drew Weissman, M.D., Ph.D., ( https://www.med.upenn.edu/apps/faculty/index.php/g275/p20322 ) is a 2023 Nobel Laureate in Medicine ( https://www.nobelprize.org/prizes/medicine/2023/summary/ ), Roberts Family Professor in Vaccine Research and Director of the Penn Institute for RNA Innovation ( https://rnainnovation.med.upenn.edu/ ). He is also a Professor in the Department of Medicine and Director of Vaccine Research in the Infectious Diseases Division at the Perelman School of Medicine at the University of Pennsylvania ( https://www.pennmedicine.org/providers/profile/drew-weissman ). Dr. Weissman is a physician-scientist and pioneer in the science of immunology, with major contributions to the field. Most notably, Dr. Weissman, and his colleagues discovered a novel nucleoside-modified mRNA platform that bypasses adverse immunologic response, which was the result of decades-long dedication and research, not just focused on modifying mRNA, but also developing a novel lipid nanoparticle delivery technique, ensuring that it could reach the proper part of the body and trigger the immune system to fight disease. This platform not only serves as the basis for the burgeoning research of targeted therapeutics for some of the world’s most devastating diseases, but paved the way for the first mRNA vaccines, being the critical backbone to the COVID-19 mRNA vaccines. Dr. Weissman and his lab team ( https://www.med.upenn.edu/weissmanlab/ ) continue to conduct basic science research to understand and develop new nucleoside-modified mRNA platforms to advance effective and safe vaccines for different types of diseases, as well as new therapeutics. Dr. Weissman and his team are currently at work on a variety of novel projects such as a pan-coronavirus vaccine to stop the next coronavirus epidemic, a universal flu vaccine, and a vaccine to prevent herpes, as well as working with Penn colleagues to develop interventions in various non-communicable diseases, such as cancer therapeutics with mRNA technology. Dr. Weissman's lab is also developing a SARS-CoV-2 mRNA vaccine with Chulalongkorn University in Thailand to help residents of Thailand and other surrounding nations with fewer financial resources than the United States access lifesaving vaccines. Before joining Penn in 1997, Dr. Weissman was a fellow at the National Institutes of Health studying HIV in the immunoregulation lab of Dr. Anthony Fauci. Dr. Weissman received his bachelor's degree and master's degree from Brandeis University, majoring in biochemistry and enzymology, and earned his MD and PhD working in immunology and microbiology at Boston University and completed his residency at Beth Israel Hospital. Support the show

Send us a textDr. David Grier, Ph.D. is Professor of Physics and Director of the Center for Soft Matter Research, at NYU ( https://as.nyu.edu/features/meet-faculty-of-as/david-grier.html ). Dr. Grier’s research focuses on experimental soft condensed matter physics—an interdisciplinary field that includes physics, chemistry, biology, and nanotechnology, ultimately aiming to understand how objects interacting in simple ways manage to organize into sophisticated hierarchies of both structure and function. After completing a B.S. in Physics from Harvard College, a Ph.D. in Physics from University of Michigan, and two years as a postdoctoral fellow in the Condensed Matter Physics Department at AT&T Bell Laboratories, Dr. Grier accepted a faculty position at the University of Chicago, where he was a member of the physics department for 12 years. He moved to New York University (NYU) in 2004 and served as Department Chair for eight years. Dr. Grier has numerous laboratory achievements including developing state-of-the-art methods of digital video microscopy, introducing powerful new methods of holographic video microscopy, demonstrating the first practical tractor beams, the first knotted force fields, and the first optically organized micromachines. Dr. Grier’s group, as part of its National Science Foundation-funded basic research program, developed a holographic optical trapping technique, which provides the groundwork for a range of new categories of applications in photonics, medical diagnostics, drug discovery, and environmental monitoring. Dr. Grier has published over 100 peer-reviewed articles on basic research in this area and holds more than 50 U.S. Patents on technology invented in the course of this research. His efforts have been recognized with a David and Lucile Packard Foundation Fellowship. More than a dozen of his former graduate students and postdoctoral fellows have gone on to faculty positions in major universities or leadership roles in industrial research and development. Dr. Grier is also Chair of the Scientific Advisory Board, Founder and Member of the Board of Directors of Spheryx Inc. ( https://spheryx.solutions/ ), a revolutionary company leveraging his research in finding solutions to deliver better, safer products at reduced costs, and providing benefits to consumers and manufacturers across multiple industries. Support the show

Send us a textJ. Craig Venter, PhD, ( https://www.jcvi.org/about/j-craig-venter ) is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is founder, chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 120 scientists and staff dedicated to human, microbial, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics. Dr. Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in biochemistry and a PhD in physiology and pharmacology from the University of California at San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed expressed sequence tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using the new whole genome shotgun technique. In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse, and rat genomes. Dr. Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in constructing the first self-replicating bacterial cell using synthetic DNA. Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology. Dr. Venter is also a serial entrepreneur who has co-founded several companies including Synthetic Genomics, Inc., now Viridos and Human Longevity, Inc. (HLI). Dr. Venter's newest book "The Voyage of Sorcerer II: The Expedition That Unlocked the Secrets of the Ocean’s Microbiome" was recently released on September 12, 2023 - https://www.amazon.com/Voyage-Sorcerer-II-Expedition-Microbiome/dp/0674246470 Support the show

Send us a textBrigadier General (Res.) Uri Oron is Israeli Space Agency (ISA) Director ( https://www.space.gov.il/en ). ISA is a national agency operating under the auspices of the Ministry of Innovation, Science and Technology ( https://www.gov.il/he/departments/ministry_of_science_and_technology/govil-landing-page ), and they are responsible for initiating, leading and coordinating all activities of the civilian space program in Israel. Director Oron earned a bachelor’s from Auburn University at Montgomery, a Master degree with distinction from Haifa University, in National Security Policy Studies, and he is a graduate of USAF Air Command and Staff College at the US Air University and the Israel's National Security College. Director Oron served as a fighter pilot with command and operational experience of over thirty-two years in the Israel Air Force, having served in various positions, including squadrons wing commander and the head of the Israel Air Force’s Intelligence Directorate. Prior to joining the Israeli Space Agency, Director Oron managed operations in an Israeli Artificial Intelligence start-up and he has accumulated extensive experience in managing complex systems and implementing state-of-the-art technologies, based on broad-scale strategies. He has led innovative projects in the space field in collaboration with the IDF, as well as the defense industries, while also interfacing with the political echelon. Support the show

Send us a textDr. Chavonda Jacobs-Young, Ph.D. ( https://www.ree.usda.gov/biographies ) serves as the Under Secretary for Research, Education, and Economics (REE), and Chief Scientist at the United States Department of Agriculture (USDA). The REE mission area is comprised of more than 8,500 employees with a $4 billion budget across its five component organizations including the Agricultural Research Service (ARS), Economic Research Service (ERS), National Agricultural Statistics Service (NASS), National Institute of Food and Agriculture (NIFA), and Office of the Chief Scientist (OCS). Together these organizations advance agricultural research, innovation, data, and Extension across a full range of agricultural issues including climate-smart agriculture, nutrition security, equity, and strengthening food supply chains. As Chief Scientist, Dr. Jacobs-Young advises the Secretary of Agriculture and other senior officials on scientific matters and chairs the USDA Science Council, which convenes all parts of USDA’s scientific enterprise. Prior to being appointed by President Biden to serve as the REE Under Secretary, Dr. Jacobs-Young was Administrator for ARS from 2014 to 2022. Prior to that role, she served as ARS Associate Administrator for National Programs, leading the research objectives of the entire Agency. She also led the Office of International Research Programs, which is responsible for ARS' liaison with its international partners. From 2009 to 2012, Dr. Jacobs-Young served as the inaugural OCS Director, where she was responsible for facilitating the coordination of scientific leadership across the Department to ensure that research supported by, and scientific advice provided to, the Department and external stakeholders were held to the highest standards of intellectual rigor and scientific integrity. She has also served as the Acting Director for NIFA and as a senior policy analyst for agriculture in the White House Office of Science and Technology Policy. Dr. Jacobs-Young is a native of Georgia. She holds M.S. and Ph.D. degrees in Wood and Paper Science and a B.S. degree in Pulp and Paper Science and Technology from North Carolina State University. She is a graduate of American University's Key Executive Leadership in Public Policy Implementation Program, and a proud fellow of both the American Association for the Advancement of Science and the National Academy of Public Administration. Resource Links: Link to @USDAScience on X: https://twitter.com/USDAScience Link to Research, Education, and Economics website: https://www.ree.usda.gov/ Link to USDA Science and Research Strategy: https://www.usda.gov/usda-science Link to ASCEND for Better Health: https://www.nutrition.gov/topics/ascend-better-health Link to the USDA announcement about the launch of AIM for Climate: https://www.usda.gov/media/press-releases/2021/11/02/launching-agriculture-innovation-mission-climate Link to the USDA's 100th Annual Agricultural Outlook Forum, “Cultivating the Future” - https://www.usda.gov/oce/ag-outlook-forum Support the show

Send us a textDr. Anthony S. Fauci is Distinguished University Professor in the Georgetown University School of Medicine’s Department of Medicine, in the Division of Infectious Diseases ( https://medicine.georgetown.edu/divisions/infectiousdiseases/ ), an academic division that provides clinical care, conducts research and trains future physicians in infectious diseases. He also holds an additional appointment in the university’s McCourt School of Public Policy. Dr. Fauci served as U.S. National Institute of Allergy and Infectious Diseases (NIAID) Director from 1984 to 2022. He oversaw an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis, and malaria as well as emerging diseases such as Ebola, Zika and COVID-19. He also led the NIAID research effort on transplantation and immune-related illnesses, including autoimmune disorders, asthma, and allergies ( https://www.niaid.nih.gov/about/anthony-s-fauci-md-bio ) . Dr. Fauci advised seven Presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), a program that has saved more than 20 million lives throughout the developing world. Dr. Fauci was a key advisor to seven Presidents and their administrations on global HIV/AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza and COVID-19. As an HIV/AIDS researcher he was involved in the scientific effort since AIDS was recognized in 1981, conducting pivotal studies that underpin the current understanding of the disease and efforts to develop therapies and tools of prevention. Dr. Fauci was the longtime chief of the Laboratory of Immunoregulation. He made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases. He helped pioneer the field of human immunoregulation by making important basic scientific observations that underpin the current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise ways that immunosuppressive agents modulate the human immune response. He developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, granulomatosis with polyangiitis (formerly Wegener's granulomatosis), and lymphomatoid granulomatosis. Dr. Fauci made seminal contributions to the understanding of how HIV destroys the body's defenses leading to its susceptibility to deadly infections. Further, he was instrumental in developing treatments that enable people with HIV to live long and active lives. In a 2022 analysis of Google Scholar citations, Dr. Fauci ranked as the 44th most-cited living researcher. According to the Web of Science, Dr. Fauci ranked 9th out of 3.3 million authors in the field of immunology by total citation count between 1980 and April 2022. During the same period, he ranked 22th out of 3.3 million authors in the field of research & experimental medicine, and 715th out of 1.4 million authors in the field of general & internal medicine. Dr. Fauci has delivered major lectures all over the world and is the recipient of numerous prestigious awards, including the Presidential Medal of Freedom (the highest honor given to a civilian by the President of the United States), the National Medal of Science, the George M. Kober Medal of the Association of American Physicians, the Mary Woodard Lasker Award for Public Service, the Albany Medical Center Prize in Medicine and Biomedical Research,Support the show

Send us a textMr. Ian Watson currently serves as the Deputy Assistant Secretary of Defense for Chemical and Biological Defense (DASD/CBD) at the U.S. Department of Defense ( https://www.acq.osd.mil/ncbdp/leadership/bio-Watson.html ). In this capacity he is the principal advisor to the Assistant Secretary of Defense (ASD) for Nuclear, Chemical, and Biological Defense Programs (NCB) and conducts Department level research, development, and acquisition (RDA) activities from concept and requirements development, through early science and technology, to advanced development, testing and evaluation, and procurement. These efforts focus on reducing risk from emerging threats and fielding sustainable capabilities to all Services in accordance with Department, Service and Combatant Command priorities for chemical, biological, and ensure our warfighters can fight and win in chemical, biological, radiological, and nuclear (CBRN) contested environments. Previously, Mr. Ian Watson served as the Deputy Assistant Secretary, and Director of the Office of Strategy, Policy, Planning, and Requirements (SPPR), and for Industrial Base Expansion in the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. In this position, Mr. Watson was responsible for leading the policy planning life-cycle, to ensure that ASPR’s preparedness and emergency response capabilities align with the ASPR’s mission, as well as broader policy and planning considerations to support the ASPR in protecting Americans from 21st Century health security threats. Mr. Watson was also responsible for the Department’s Industrial Base Expansion, supply chain management, industrial policy, and Defense Production Act (DPA) program for the pandemic response. Mr. Watson previously served as the Assistant Director for Biotechnology and Biosecurity within the Office of Science and Technology Policy (OSTP) in the Executive Office of the President (EOP) whose mission is to ensure America is the world leader in science and technology. While at OSTP Mr. Watson worked national security and S&T policy initiatives pertaining to the Bioeconomy, biodefense, planetary protection, scientific collections, biological sciences, etc. Prior to being detailed to OSTP, Mr. Watson was in the Department of Defense, where he has previously served in multiple positions as a leader for Countering Weapons of Mass Destruction research, development, implementation, policy; systems integration for missile defense; Countering Threat Networks and Counter Proliferation initiatives; and managing and developing interagency and international relationships under Cooperative Threat Reduction, foreign military sales, and international armaments cooperation. Mr. Watson’s graduate background includes degrees in international relations, biodefense, and public health. Support the show

Send us a textCraig Thompson is the Chief Executive Officer of Cerevance ( https://www.cerevance.com/about ), a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology, a machine learning platform that helps measure precise levels at which thousands of genes are expressed in any cell type in any region of the brain, and then map those genes to specific diseased and healthy brain states. Most recently, Mr. Thompson was President and Chief Executive Officer of Neurana Pharmaceuticals. Prior to Neurana, Mr. Thompson was President and Chief Executive Officer of Anthera Pharmaceuticals. Mr. Thompson's previous biotech experience includes Chief Operating Officer for Tetraphase Pharmaceuticals and Chief Commercial Officer for Trius Therapeutics where he was involved in the $707M up front acquisition of Trius by Cubist Pharmaceuticals, as well as a partnership with Bayer Pharma AG. Prior to Trius, Mr. Thompson served in various global and U.S. roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and ultimately served as Vice President of Marketing for Pfizer’s Specialty Care Business Unit. Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc including leading the partnership with Schering Plough. Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame. Support the show

Send us a textProfessor Ibrahim Abubakar, FMedSci is Pro-Provost (Health), Dean, Faculty of Population Health Sciences and Professor of Infectious Disease Epidemiology, University College London ( UCL - https://www.ucl.ac.uk/tb/people/professor-ibrahim-abubakar ). He was previously director of the UCL Institute for Global Health until July 2021. Prof. Abubakar was appointed National Institute for Health and Care Research (NIHR) Senior Investigator in 2017 and elected Fellow Academy of Medical Sciences in 2020. He led the UCL Centre for Infectious Disease Epidemiology, UCL-TB and was a senior investigator at the Medical Research Council (MRC) Clinical Trials Unit. He was also head of TB at Public Health England and prior to his appointment at UCL, he was Professor in Health Protection at the Norwich Medical School. Prof. Abubakar qualified in medicine in 1992 and initially trained in general medicine before specializing in public health medicine. His academic public health training was undertaken at London School of Hygiene & Tropical Medicine (LSHTM), University of Cambridge and the University of East Anglia. Prof. Abubakar is a member of the Global Preparedness Monitoring Board ( https://www.gpmb.org/ ), Chair of Lancet Migration: global collaboration to advance migration health, Lancet Nigeria Commission and the NIHR Global Health Professorship Committee. He also served as chair of the WHO Strategic and Technical Advisory Group for Tuberculosis until 2019 and of the Wellcome Trust Expert Review Group on Population Health until 2022. Support the show